With only 4% of drug candidates reaching the clinical phase, developing oncology treatments is a major challenge that Orakl Oncology aims to tackle with an innovative technology combining biology and artificial intelligence: tumor avatars.
These avatars, built from patients’ biological data, replicate how tumors respond to specific treatments. Each avatar corresponds to a patient and their pathology, enabling researchers to assess the effectiveness of drug candidates.
The startup is currently focusing its efforts on digestive cancers, including pancreatic cancer, which is increasingly affecting younger populations, and colorectal cancer, the second leading cause of cancer-related deaths. By expanding its current collection of a hundred avatars to 1,000 by 2026, Orakl Oncology aims to provide powerful predictive tools to biopharma and biotech players.
To support this expansion, Orakl Oncology has raised €11 million from Singular Capital Partners. This funding will be used to strengthen its team, currently composed of 14 members, with ten new hires planned over the next 12 months, as well as to enhance its commercial and R&D capabilities.
